On January 16, 2020 Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks, reported that it has been granted an exclusive, worldwide sublicense by SATT Sud-Est to the immunoconjugates of the anti‑CD146-ts antibody (excluding diagnosis), which binds a tumor-specific form of CD146 found on a number of solid cancers (Press release, Syndivia, JAN 16, 2020, View Source [SID1234553294]). CD146-ts has a central role in the mechanism of tumorigenesis and has the potential to address a current unmet need in cancer therapy. The development of novel biologic entities (NBE) targeting CD146-ts will be undertaken by Syndivia in Strasbourg, France.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Commenting on this deal, Dr. Sasha Koniev, Syndivia’s CEO, said "We are excited to have been granted the sole and exclusive sublicense to commercialize the immunoconjugates against this tumor-specific form of CD146. We are enthusiastic about the addition of this candidate to the Syndivia discovery pipeline and will leverage our expertise in bioconjugation to rapidly progress its preclinical development."

"We are extremely pleased that Syndivia shares our excitement for the CD146-ts mAb project and look forward to the next stages of development with great enthusiasm," said Dr. Marcel BLOT-CHABAUD, inventor of anti-CD146-ts antibody and leader of the "New Molecular Targets" team at C2VN, Aix-Marseille Université, INSERM, INRA, Marseille, France.

"We could not be any happier when transferring such a first-in-class opportunity for the treatment of solid cancers, with the sole aim of transforming the invention into an innovation – especially when the nature of the identified target makes it possible to identify a relevant lead for the most aggressive and refractory forms to current treatments," concluded Laurent BALY, President of SATT Sud-Est.

Syndivia will undertake further development and commercialization of anti-CD146-ts immunoconjugates in exchange for undisclosed upfront, milestone and royalty payments to SATT Sud-Est.

About CD146-ts

CD146-ts represents a novel target in a number of the deadliest therapeutic indications in oncology, including melanoma and pancreatic cancer. Due to its important role in tumorigenesis and confirmed tumor-specific expression in patient-derived samples, anti-CD146-ts immunoconjugates have the potential to become new therapeutic modalities in a number of solid cancer indications.

About C2VN (Aix-Marseille Université, INSERM, INRA)

The Cardiovascular and Nutrition Research Centre (C2VN, UMR_S 1263, UMR 1260, Aix-Marseille Université, INSERM, INRA) shows expertise in all pathways and targets involved in pathologies with a vascular component, including cancer pathology, with the aim of identifying innovative biomarkers and biotherapies. To support its studies, the C2VN has developed many platforms, tools and experimental models related to the targeted pathologies. For more information, visit View Source

About SATT Sud-Est ­| From dream to reality, from lab to market

A researcher and his/her team make an extraordinary discovery. But how can an idea be transformed into a solution, and how can an invention be turned into an innovation? This is the start of a race against time to find the partner company capable of upholding that ambition. Fortunately, SATT Sud-Est is there to help in this undertaking and make this great story come true. Transforming an invention into an innovation is a wonderful experience. And we’re fortunate, it is our job. Find out how SATT Sud-Est accelerates technology transfer by bringing together research and business players. From the patent to the operating license agreement, SATT Sud-Est stands out in France’s South and Corsica regions as an essential innovation player. Visit www.sattse.com and Twitter @SATTse_.

On January 16, 2020 MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX), dedicated to the early detection of skin cancer, reported that a total of 5,990,000 stock options have been granted to directors (2,020,000 options), Officers (1,580,000 options) and employees and consultants (2,390,000 options) (Press release, MedX Health, JAN 16, 2020, View Source [SID1234553293]). The options are all exercisable at the price of $0.17 per share, valid for a period to December 31, 2024, and vest immediately. The Company notes that a total of 7,150,000 stock options previously granted in 2014 expired unexercised on November 26, 2019. At this time there are a total of 21,200,000 options available for grant under the Company’s Incentive Stock Option Plan, of which a total of 17,765,000 are currently subject to grants, at a weighted average exercise price of $0.197, and 3,435,000 remain available for grant under the Plan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 16, 2020 Physicians’ Education Resource (PER), a leading resource for continuing medical education (CME), reported that it will host the 5th Annual School of Gastrointestinal Oncology on Saturday, March 21, at the MGM National Harbor in Oxon Hill, Maryland (Press release, Physicians’ Education Resource, JAN 16, 2020, View Source [SID1234553292]). The program will be co-chaired by world-renowned experts John L. Marshall, M.D., chief, division of hematology/oncology, Medstar Georgetown University Hospital; professor of medicine and oncology, Lombardi Comprehensive Cancer Center; and director, The Ruesch Center for the Cure of Gastrointestinal Cancers; and Michael A. Choti, M.D., MBA, FACS, chief of surgery, Banner MD Anderson Cancer Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The gastrointestinal (GI) cancer landscape is constantly transforming, as is the growing number of therapies and treatment options," said Phil Talamo, president of PER. "This conference will educate attendees on how precision medicine has changed the treatment landscape and how to properly use precision medicine to optimize patient care and outcomes."

SOGO is a one-day, multidisciplinary educational conference, dedicated to exploring emerging therapies and evolving standards of care in the management of patients with GI tumors, with a focus on providing oncologists and gastroenterologists with the tools to individualize patient care. The program includes various modules that feature general presentations and workshops geared toward important concepts in the field. With separate tracks in medical oncology, surgical and radiation oncology, and case-based SOGO seminars, the program is designed to match the learning interests of everyone who attends.

This year’s symposium will once again feature the dynamic and interactive Medical Crossfire format, in which experts will engage in debate and answer questions about ongoing paradigm shifts. The program will also feature case-based lectures by expert faculty that explore the latest data and how it can affect decisions to improve outcomes for patients.

On January 16, 2020 Mundipharma reported a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong (Press release, Mundipharma, JAN 16, 2020, View Source [SID1234553291]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).

Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.

"This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments," said Mundipharma CEO, Raman Singh. "This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments," he added.

On January 16, 2020 AgilVax, Inc., a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint, and KRAS inhibitors, reported that it closed an expansion of its Series A-1 financing with an additional investment of $1.5 million from its existing investors, bringing the total capital raised to nearly $10 million (Press release, Agilvax, JAN 16, 2020, View Source [SID1234553290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This additional investment reflects the confidence of our existing investors and allows AgilVax to continue generating compelling preclinical data with our monoclonal antibody-drug conjugates targeting SLC7A11 (xCT)," stated Dr. Joseph Patti, President and Chief Executive Officer of AgilVax. Dr. Patti further stated, "xCT overexpression is often associated with KRAS mutations in several cancers and its biological role is involved with critical cellular metabolic changes that lead to tumor progression. AgilVax’s antibody-based therapeutics have shown the ability to reduce primary tumor formation and the number of lung metastases in an animal model illustrating the potential to create durable responses in patients suffering from various metastatic cancers."

Ebetuel Pallares, PhD, AgilVax’s Chairman, said, "The team is making excellent progress developing their antibody-based programs for multiple oncology indications and we are excited to support this important research."